Table of contents
Trial overview
The clinical trial NCT06072326 was an interventional study, which means researchers planned to assign treatments and then measure what happened.[1] It studied N-[5-(2H-1,3-BENZODIOXOL-5-YL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]-N’-(2-METHOXYETHYL)SULFURIC DIAMIDE in adults with chronic kidney disease and type 1 diabetes.[1]
The brief summary says the study aimed to compare dapagliflozin plus the study drug versus the study drug alone for albuminuria, which means too much albumin in the urine.[1]
Who was studied
The target population was adults with type 1 diabetes and chronic kidney disease who had elevated urinary albumin excretion.[1] This means the study focused on people whose kidneys were already affected and who were losing extra albumin in the urine.[1]
The trial planned to enroll 36 participants.[1] That small number is common in early-stage studies that look closely at whether a treatment may help in a specific group.[1]
What the study measured
The main endpoint was the change from baseline in urine albumin-creatinine ratio (UACR).[1] Baseline means the starting measurement before treatment begins.[1] UACR is a urine test that helps show how much albumin is leaking into the urine, so it is often used to track kidney-related changes.[1]
The primary comparison was SC0062 alone versus the combination of dapagliflozin and SC0062.[1] The source data do not list other outcomes, so the main focus described here is the UACR result.[1]
Trial phase and status
This study was in Phase 2.[1] Phase 2 trials usually look more closely at whether a treatment may work in a defined patient group while continuing safety checks.[1]
The trial status was Withdrawn.[1] In practical terms, this means the study did not go ahead as planned and the source data do not provide trial results.[1]
Key patient terms
Albuminuria means too much albumin is present in the urine, which can be a sign of kidney damage.[1] Combination treatment means two treatments are used together in the same study.[1]
Elevated urinary albumin excretion means the body is passing more albumin into the urine than normal.[1] In this trial, that feature helped define who could be studied.[1]
